

pandemic response catalyst conversations: Vaccines and Therapies and the Need for Speed

Speaker Bios



at the University of Glasgow.

David Onions, PhD BVSc MRCVS FMedSci FRSA FRSE, was President of Q-One Biotech, a company involved in the GMP production and safety evaluation of vaccines biotechnology products. The company was sold in 2003, becoming part of the Invitrogen Life Technology Corporation, where David became the Chief Medical Officer. In 2007, he was involved in a buyout of the BioReliance corporation with Avista Capital Partners; he was also a founder shareholder of BioOutsource and is on the board of several biotech companies. Formerly, he was Director of the Leukaemia Research Fund's Virus Centre and Professor of Veterinary Virology

David has been awarded the Norman Hall Gold Medal for Research into Animal Diseases from the Royal College of Veterinary Surgeons, the Animal Health Trust Award for Outstanding Scientific Achievement and the British Veterinary Association's Cup and Medal for contributions to veterinary science. In 2006, he received an Honorary Doctorate from the University of Glasgow for services to biotechnology and veterinary medicine. David is a member, or former member, of several advisory groups, including the UK Advisory Committee on Release of GMOs Into the Environment, the FDA xenotransplantation advisory committee, the World Health Organization's Expert Advisory Panel on Biological Standardization and the UK Medical Research Council Stem Foundation.



clinically important antibiotic.

Jared Silverman, PhD, is Head of Translational Discovery at the Gates Medical Research Institute. He trained as a microbiologist, working on a variety of problems in microbial pathogenesis. He previously served as Senior Vice President at Kaleido Biosciences, developing a drug discovery research platform for the microbiome. Prior to Kaleido, he spent 18 years at Cubist Pharmaceuticals, the last five as Vice President, Biology. At Cubist, he contributed to the discovery of three novel antibiotics that entered clinical development and lead key studies into the mechanism of action of the lipopeptide antibiotic daptomycin and the mechanisms of resistance to this

Jared serves as an advisor to the Medical Research Council (UK) on antibiotic resistance, as an editor of *Antimicrobial Agents and Chemotherapy*, as a member of multiple grant review panels (NIH, CarbX) and as a consultant in antibiotic discovery. Jared holds an AB in Molecular Biology from Princeton, received a PhD in Microbiology from Harvard Medical School and completed postdoctoral training at Yale University.



Audrey Chang, PhD, earned her PhD in Biology at The Johns Hopkins University, Baltimore, Maryland, and has over 25 years of government and industry experience in conducting biological products testing and in managing laboratories. In her current role as Head of Process Solutions Services R&D at MilliporeSigma, she is responsible for managing and developing a team of PhD-level scientific experts that provides greater focus to the development of new services and technologies while providing technical solutions and support to clients and operating laboratories. She and her department work to identify emerging products, technology trends and global regulatory requirements and champion activities to implement new business plans.



Karl Schmieder, MS/MFA, is the founder and CEO of messagingLAB, a strategic marketing and communications agency that helps life sciences companies grow their business. An award-winning author, Karl has worked with two-person startups and Fortune 10 companies helping create strategies to generate hundreds of millions of dollars. Karl teaches Fortune 500 companies, associations and students how to develop a business strategy that leverages the power of biology. He speaks regularly on the impact of biotechnology on innovation, localization, supply chains and business growth.

Karl is the co-author of *What's Your Bio Strategy? Preparing Your Business for Synthetic Biology*. He is an adviser to IndieBio New York and currently works with several venture funds analyzing potential investments and partnerships. Prior to founding messagingLAB, Karl served as Chief Strategy Officer at Medikly and Chief Marketing Officer at One Eleven Software, two digital health firms. He served as Vice President at the interactive agency, Xceed Inc., Vice President Media Relations at GCI Group and Director, Marketing Communications at Noonan/Russo Communications.



Jehangir Mistry, PhD, is the Head of R&D for MilliporeSigma's Chemistry business, where his team is focused on developing novel chemical building blocks, reagents and workflow solutions that enable chemists and biologists to accelerate their Drug Discovery Research. Jehangir possesses multidisciplinary background, including Organic/Medicinal Chemistry, Chemical Technology, Protein Biochemistry, Cell Biology, Cancer Pharmacology and in vitro Diagnostics. During his more than 27 years of industrial career, he has held multiple positions of increased responsibility, including Director of R&D for Antibody and Immunoassay Platform Development, Protein Detection and Cell Analysis Reagents, Automated Systems Development, Director of Manufacturing and Marketing and General Management.

Jehangir was born in Mumbai, India, where he received his BS degrees in Chemistry and Chemical Technology and MS in Technology of Pharmaceuticals and Fine Chemicals. He received his PhD in Medicinal Chemistry with emphasis on Neurochemistry of Aging from the University of Pittsburgh and conducted his postdoctoral research studying mechanisms of Cancer Drug Resistance.